Abstract
Background: COVID-19 is a current global threat and characterisation of antibody response to SARS-CoV-2 is vitally important to update vaccine development and strategies.Methods: In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N=272) and subjects vaccinated with BNT162b2 m-RNA Covid-19 vaccine (N=1,256). For each participant socio-demographic data, COVID-19 vaccination records, serological analyses and SARS-CoV-2 infection status have been collected. IgM and IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected.Findings: Almost all vaccinated subjects (99·8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% vaccinated subjects had IgG concentrations >200 AU/mL. SARS-CoV-2 subjects had IgG concentrations Interpretation: Our findings could support the vaccination campaigns confirming the high immunogenicity of the SARS-CoV-2 vaccine under investigation also with respect to the natural infection. Further studies will be required for evaluating the role of age and days after immunization in the persistence of vaccine antibodies and protection from the disease.Funding Statement: None to declare. Declaration of Interests: None to declare.Ethics Approval Statement: The study has been approved by the Ethical Committee of the A.O.U.P. “P. Giaccone” on June 24th, 2020, protocol number 0006.
Highlights
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by Severe AcuteRespiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]
A statistically significantly difference was found among the distribution of IgG concentrations between the two cohorts with more than 80% of vaccinated subjects having concentrations above 200 AU/mL, whereas more than 80% of SARS-CoV-2 subjects had
According to the worst clinical presentation, a large majority of subjects included in the SARS-CoV-2 Cohort were asymptomatic to mild (243; 89.3%), whereas 25 (9.2%) were moderate and 4 (1.5%) were severe/critical
Summary
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]. It was reported for the first time in Wuhan (China) in December 2019 [2,3,4] and, from that time, it spread globally, resulting in a pandemic. SARS-CoV-2 infection might pass asymptomatically or there might be symptoms that evolve into a mild, moderate, severe, or critical disease [6]. A range of clinical and policy interventions have been implemented in order to mitigate SARS-CoV-2 spread; a better understanding of the dynamics and determinants of humoral immunity to this virus and to the new available vaccines could represent a major piece in the puzzle in the fight against the virus
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
